Breast Cancer Diagnostics Market

Global Breast Cancer Diagnostics Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2023-2029- The market will expand due to the rising cases of breast cancer, growing awareness about breast cancer screening and early detection, and increasing demand for personalized medicine and targeted therapies.

Global Breast Cancer Diagnostics Market is valued at USD 4.07 Billion in 2022 and it is expected to reach USD 6.58 Billion by 2029 with a CAGR of 7.1% over the forecast period.

Scope of Global Breast Cancer Diagnostics Market Report-

Breast cancer diagnostics involves the use of various techniques and tools to detect the presence of breast cancer. The history of breast cancer diagnostics dates back to the early 1900s when mammography was first introduced. Over the years, advancements in technology and research have led to the development of newer and more effective diagnostic tools such as ultrasound, MRI, and genetic testing.

The application of breast cancer diagnostics is crucial in the early detection and timely treatment of breast cancer. The end users of breast cancer diagnostics include healthcare professionals, patients, and medical researchers.

Breast cancer genetic testing is a type of diagnostic test that analyzes DNA in blood or other tissue samples to identify genetic mutations or alterations that may increase the risk of developing breast cancer. This type of testing can help identify individuals who may be at higher risk of developing breast cancer and inform decisions about screening and preventive measures.

Revenue Generation Model:

The revenue generation model for the breast cancer diagnostics market involves the sale of diagnostic equipment, reagents, and testing services to hospitals, diagnostic laboratories, and other healthcare facilities. Companies in the market generate revenue through the sale of these products and services, as well as through partnerships and collaborations with other companies in the healthcare industry.

Supply Chain Analysis:

The supply chain model for the breast cancer diagnostics market involves multiple stakeholders, including manufacturers, distributors, and end-users. Manufacturers produce and supply diagnostic equipment, reagents, and testing services, which are then distributed to hospitals, diagnostic laboratories, and other healthcare facilities. End-users, such as healthcare professionals and patients, then use these products and services for the diagnosis and treatment of breast cancer.

Value Chain Analysis:

The value chain model for the breast cancer diagnostics market includes several stages, starting with research and development of new diagnostic tools and techniques, followed by manufacturing and distribution, and ultimately ending with the use of these products and services for the diagnosis and treatment of breast cancer. The value chain model also includes marketing and sales efforts to promote the adoption and use of these products and services by healthcare professionals and patients.

Covid-19 Impact on the Global Breast Cancer Diagnostics Market:

The Covid-19 pandemic has had a significant impact on the breast cancer diagnostics market. The pandemic has led to disruptions in the supply chain, delays in diagnosis and treatment, and changes in patient behavior that have affected the demand for diagnostic tests. The lockdowns and social distancing measures implemented to control the spread of Covid-19 have led to a reduction in the number of screenings and diagnostic tests for breast cancer. Patients have been hesitant to visit healthcare facilities for fear of contracting the virus, and healthcare resources have been redirected toward Covid-19 patients.

However, the pandemic has also led to innovations in the breast cancer diagnostics market. The use of telemedicine and remote monitoring technologies has increased, allowing healthcare professionals to continue to provide care to patients while minimizing the risk of exposure to the virus.

Overall, the Covid-19 pandemic has had a mixed impact on the breast cancer diagnostics market. While the disruptions and delays have led to a reduction in demand, the innovations and changes in patient behavior may lead to new opportunities for growth in the market.

Key Players of Global Breast Cancer Diagnostics Market Report-

• Abbott Laboratories
• Agilent Technologies
• Becton Dickinson and Company
• Bio-Rad Laboratories
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• GE Healthcare
• Hologic Inc.
• Illumina Inc.
• Koninklijke Philips N.V.
• Myriad Genetics Inc.
• NanoString Technologies Inc.
• NeoGenomics Laboratories Inc.
• OPKO Health Inc.
• PerkinElmer Inc.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Genomic Health
• Grail
• Guardant Health
• Invitae Corporation
• Natera Inc.
• Foundation Medicine
• Exact Sciences Corporation
• QIAGEN N.V.
• Sysmex Corporation
• Volpara Health Technologies
• Oncotype DX
• Mammostrat

Global Breast Cancer Diagnostics Market Segmentation:-

By Test Type:

• Imaging
• Biopsy
• Genomic tests
• Blood tests
• Others

By Product:

• Platform-based Products
• Instrument-based Products

By Technology:

• Fluorescent In Situ Hybridization (FISH)
• Comparative Genomic Hybridization (CGH)
• Immunohistochemical (IHC)
• Other

By Cancer Type:

• Ductal carcinoma in situ (DCIS)
• Invasive ductal carcinoma (IDC)
• Invasive lobular carcinoma (ILC)
• Medullary carcinoma
• Mucinous carcinoma
• Tubular carcinoma
• Papillary carcinoma
• Other

By Application:

• Screening
• Diagnostic
• Monitoring
• Prognostic
• Others

By End-User:

• Hospitals
• Clinics
• Research and Academic Institutes
• Diagnostic Centers
• Other

By Regional & Country Level:

• North America
  • S.
  • Canada
• Europe
  • K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • GCC
  • Africa

Rest of Middle East and Africa

Market Drivers:

Growing awareness about breast cancer screening and early detection: Early detection of breast cancer significantly improves the chances of successful treatment and survival. This has led to an increasing demand for screening and diagnostic tests, including mammography, ultrasound, MRI, and biopsy, among others. The National Cancer Institute (NCI) reports that digital breast tomosynthesis (DBT), also known as 3D mammography, has been shown to improve breast cancer detection rates and reduce the number of false positive results compared to traditional 2D mammography.

Moreover, advancements in breast cancer diagnostic technology, such as genomic testing for breast cancer and genetic screening for breast cancer, have improved the accuracy and reliability of diagnostic tests.

BRCA genetic mutation testing and BRCA screening, which are used to detect the risk of breast cancer in women with a family history of the disease, have also gained popularity. For example, approximately 50 out of 100 women with a BRCA1 or BRCA2 gene mutation have a significantly higher risk of developing breast cancer by the age of 70, compared to only 7 out of 100 women in the general United States population.

The breast cancer diagnosis rate has increased significantly due to growing awareness and availability of breast diagnostic tests. As a result, more women are getting screened and diagnosed with breast cancer at an early stage, which is critical for effective treatment and improved outcomes.

Rising demand for personalized medicine and targeted therapies: The increasing need for personalized medicine and targeted therapies in breast cancer treatment is a significant driver of the breast cancer diagnostics market. Genomic testing helps identify genetic mutations and biomarkers in patients, leading to better-targeted therapies. Targeted therapies are more effective with fewer side effects, especially for hereditary or genetically mutated breast cancer.

For example; in the United States, around 15% of the estimated 276,480 new cases of breast cancer in 2020 were HER2-positive. The FDA has approved a new HER2-targeted therapy called Tucatinib (Tukysa) for patients with advanced or metastatic HER2-positive breast cancer that has not responded to previous treatments with other HER2-targeted therapies.

Advancements in breast cancer medicine, science, vaccine, and drug trials have increased the demand for diagnostics that can identify genetic mutations and biomarkers, facilitating personalized treatment plans. The rising demand for personalized medicine and targeted therapies is expected to drive market growth.

Market Restraints:

One of the restraining factors for the breast cancer diagnostics market is concerns regarding the accuracy and reliability of some breast cancer diagnostic tests:

While there are many advanced technologies and tests available for diagnosing breast cancer, some of them may not be as accurate or reliable as others, leading to false positive or false negative results. This can result in unnecessary diagnostic procedures or delayed treatment, which can have serious consequences for patients. In addition, there may be limitations in the availability and accessibility of some breast cancer diagnostic tests, particularly in some regions where resources may be limited.

Therefore, ongoing research and development, clinical trials, and improvements in genetic screening and testing for breast cancer are necessary to address these concerns and improve the accuracy and reliability of breast cancer diagnostics.

Market Opportunities:

The growing demand for non-invasive breast cancer diagnostic tests, such as blood tests, presents a significant opportunity for the market: As these tests offer greater convenience and ease of use for patients. Unlike traditional diagnostic tests, which may require invasive procedures such as biopsies or mammograms, blood tests can be performed quickly and easily in a doctor's office or lab. This can greatly reduce patient discomfort and anxiety and also make it easier for patients to access and receive regular diagnostic testing.

Additionally, non-invasive tests can provide more accurate and reliable results, as they are less susceptible to errors or variations caused by differences in equipment or operator skill. As such, the growing demand for non-invasive breast cancer diagnostic tests is expected to drive significant growth in the market in the coming years.

The increasing adoption of AI and ML in breast cancer diagnostics presents a significant opportunity for the market: As these technologies have the potential to greatly improve accuracy and efficiency in the diagnostic process. By analyzing large amounts of patient data, AI and ML algorithms can identify patterns and make predictions that may not be apparent to human clinicians. This can lead to earlier detection of breast cancer, more accurate diagnosis, and more personalized treatment plans for patients.

Additionally, the use of AI and ML can reduce the time and resources required for diagnosis, allowing clinicians to see more patients and improve overall efficiency. As these technologies continue to improve and become more widely adopted, they are expected to drive significant growth in the breast cancer diagnostics market.

Market Trend:

Product and Technology Development Trends:

The trend in product and technology development in breast cancer diagnostics is toward the use of more advanced and innovative techniques, such as AI and ML, as well as non-invasive tests like blood tests. These new technologies and techniques are being developed to improve the accuracy and efficiency of breast cancer diagnostics and to make the process more convenient and accessible for patients.

Additionally, there is a trend toward the development of more personalized diagnostic tests that can better identify individual patient risks and guide treatment decisions. This involves the use of genetic testing and biomarkers to identify specific mutations or protein markers that may be associated with an increased risk of breast cancer.

Customer Trends:

In terms of customer trends, there is a growing focus on patient-centered care, with patients seeking greater involvement in their healthcare decisions and treatment plans. This has led to the development of more patient-friendly and non-invasive breast cancer diagnostic technologies, as well as greater emphasis on personalized medicine and targeted therapies. Patients are also seeking greater access to breast cancer diagnostic services, including through telemedicine and remote patient monitoring, to improve convenience and reduce the need for in-person visits.

Market Competition Nature:

Competition in the breast cancer diagnostics market is intense, with numerous players competing to offer the most accurate, efficient, and accessible diagnostic tests to patients. The market is dominated by a few key players, including Hologic, Inc., GE Healthcare, Siemens Healthineers, Becton, Dickinson and Company, and F. Hoffmann-La Roche Ltd, among others.

To stay competitive, key market players have implemented various strategies in the past, including mergers and acquisitions, partnerships and collaborations, and product innovation and development. For example, Hologic recently acquired Focal Therapeutics to expand its breast health product offerings, while GE Healthcare has partnered with Invicro to develop AI-based diagnostic tools for breast cancer. Similarly, Siemens Healthineers has invested in developing AI-driven imaging solutions for breast cancer diagnosis, while Becton, Dickinson, and Company have launched new breast cancer diagnostic products based on flow cytometry technology.

In the future, key market players are expected to continue focusing on product innovation and development, with a particular emphasis on the use of AI and ML in breast cancer diagnostics. Additionally, collaborations and partnerships with academic institutions and research organizations are expected to become more common as companies seek to gain access to the latest research and technology. Some companies may also look to expand into new geographic regions or market segments to drive growth and increase their market share.

Geography Analysis:

North America:

North America is expected to capture a major share of the global breast cancer diagnostics market. The region has a high incidence of breast cancer, and growing focus on early detection and diagnosis of the disease. The market is also driven by favorable reimbursement policies, increasing healthcare spending, and the presence of major market players in the region. In the United States, mammography is the most commonly used breast cancer screening method, and the American Cancer Society recommends annual mammography screenings for women beginning at age 40.

Other breast cancer diagnostic methods used in the region include breast ultrasound, breast MRI, and biopsy procedures. According to a 2020 report by the American College of Radiology (ACR), approximately 10.2 million breast ultrasounds were performed in the United States in 2018, which represents a 6% increase from the previous year

In addition to traditional imaging and diagnostic methods, there is a growing interest in the development of new, innovative diagnostic tools and technologies, such as liquid biopsy and molecular imaging. These new technologies have the potential to improve the accuracy and speed of breast cancer diagnosis and to enable more personalized treatment plans for patients.

Europe:

In Europe, breast cancer diagnostics market is set to grow due to rising awareness, increasing incidence, and adoption of advanced technologies. In Europe, breast cancer is the most common cancer among women, accounting for nearly 30% of all female cancers. According to the latest data from the International Agency for Research on Cancer (IARC), there were an estimated 562,500 new cases of breast cancer in Europe in 2020, and 137,700 deaths from the disease.

The breast cancer diagnostics market in Europe is expected to continue to grow in the coming years due to increasing awareness of breast cancer screening and the rising incidence of the disease. In addition, the increasing adoption of advanced diagnostic technologies, such as digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), and positron emission tomography (PET) is also driving the growth of the market.

Key Benefits of Global Breast Cancer Diagnostics Market Report–

• Global Breast Cancer Diagnostics Market report covers in-depth historical and forecast analysis.
• Global Breast Cancer Diagnostics Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Breast Cancer Diagnostics Market report helps to identify opportunities in the marketplace.
• Global Breast Cancer Diagnostics Market report covers extensive analysis of emerging trends and competitive landscape.